Clinical trialPhase 1Terminated
A Study of SGN-CD228A in Advanced Solid Tumors
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
- Outcome
- Stopped earlyStudy closed due to portfolio prioritization (Business decision)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 3 September 2019
- Ended
- 9 March 2023
- Enrollment
- 88 participants
- Sites
- 14
- Primary outcomes
- Number of participants with adverse events; Number of participants with laboratory abnormalities; Number of participants with dose limiting toxicities
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 23 March 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Detailed description public domain (ClinicalTrials.gov)
This study is designed to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. The study will include dose escalation and dose expansion, with multiple disease-specific expansion cohorts.